$OTLC News
Last published 2w ago
- 2w agoOTLCOncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer SignatureGlobeNewswireStudy combines AI-guided literature investigation with gene-expression analysis to identify a four-gene signature for Sapu003 development Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 26, 2026
- 3w agoOTLCOncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled DiscoveryGlobeNewswireSaran Saund to connect the emerging research approach with PDAOAI intellectual property, plans for 100 billion biological vectors, individual researcher access through Fastbot/Membot and an HCC case study AGOURA HILLS,
- 2mo agoNGTFOTLCNightfood Holdings Highlights Robotics Progress in Shareholder UpdateGlobeNewswireIRVINE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- via IBN -- Nightfood Holdings, Inc. (OTCQB:NGTF), doing business as TechForce Robotics ("TechForce" or the "Company"), today provided shareholders
- 3mo agoNPMMFPCUUFTCVNFLBSR+15OTCQB Virtual Investor Conference Presentations Now Available for On-Demand ViewingGlobeNewswireNEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the presentations from the August 5th & 6th OTCQB Virtual Investor Conference
- 3mo agoOTLCOncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thGlobeNewswireAGOURA HILLS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Onoctelic Therapeutics Inc. (OTCQB:OTLC), based in Agoura Hills, focused on Oncology Drug Development, today announced that Dr. Vuong Trieu, CEO and Chairman,
- 3mo agoNPMMFPCUUFTCVNFLBSR+14OTCQB Virtual Investor Conference Agenda Announced for August 5 & 6GlobeNewswireNEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the OTCQB Virtual Investor Conference to be held August 5th - 6th.
- 3mo agoOTLCOncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)GlobeNewswireAGOURA HILLS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in Biomedicines describing the
- 4mo agoOTLCOncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion UnderwayGlobeNewswireClinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle™ Platform SAN DIEGO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Oncotelic (OTCQB:OTLC), an
- 4mo agoOTLCOncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003GlobeNewswirePublication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle™ Technology for Hydrophobic Therapeutics SAN DIEGO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Oncotelic
- 4mo agoOTLCOncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026GlobeNewswireCompany to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical Manufacturing AGOURA HILLS, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.
- 4mo agoNGTFOTLCTechForce Robotics Advances Pharmaceutical Automation Initiative Through Phase 2 Deployment of PUR-E at SAPU Bio OEB-5 Sterile Injectable cGMP FacilityGlobeNewswireSAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- via IBN -- TechForce Robotics, Inc. ("TechForce"), a subsidiary of Nightfood Holdings, Inc. (OTCQB:NGTF), today announces the advancement of Phase 2 objectives under
- 4mo agoOTLCOncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing ServicesGlobeNewswireSAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC) today announced the completion of key Phase 2 objectives in its joint manufacturing
- 5mo agoOTLCNetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery TechnologiesGlobeNewswireAUSTIN, Texas, June 05, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled "How Advanced Drug Delivery Could Improve Existing Cancer Treatments," featuring Oncotelic
- 5mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology TherapiesGlobeNewswireNEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic
- 5mo agoOTLCSapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b ProgramGlobeNewswireSAN DIEGO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection)
- 5mo agoCYDYMRNAOTLCRVMD+1Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 BillionGlobeNewswireAUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are
- 5mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical InfrastructureGlobeNewswireNEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic
- 5mo agoHIVEIOVANWBOOTLC+1How Advanced Drug Delivery Could Improve Existing Cancer TreatmentsGlobeNewswireAUSTIN, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are
- 5mo agoNGTFOTLCTechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic TherapeuticsGlobeNewswireDeployment of the Company's LIM-E autonomous laboratory support robot completes Phase 1 objectives under the joint development agreement and establishes a foundation for future pharmaceutical automation initiatives
- 6mo agoOTLCOncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic ProgressGlobeNewswireAgoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic" or the "Company"), a clinical-stage biotechnology company focused on oncology, AI-enabled drug development,
- 6mo agoOTLCNetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB LimitationsGlobeNewswireAUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled "CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities," featuring
- 6mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery PlatformGlobeNewswireNEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic
- 6mo agoABBVAMGNJNJLNAI+1CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchGlobeNewswireAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a
- 6mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen TherapiesGlobeNewswireNEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic
- 6mo agoCYDYMRNANWBOOTLCCNS Drug Delivery Breakthroughs Unlock Significant Biotech Market OpportunitiesGlobeNewswireAUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the
- 6mo agoOTLCOncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer's DiseaseGlobeNewswireAGOURA HILLS, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic" or the "Company"), a late-stage clinical biopharmaceutical company focused on oncology and rare
- 6mo agoOTLCOncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific AbstractsGlobeNewswireLOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a clinical-stage biotechnology company focused on oncology and AI-driven solutions,
- 6mo agoOTLCNetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development PathwaysGlobeNewswireAUSTIN, Texas, April 24, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled "When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation
- 6mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on EvaluationGlobeNewswireNEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic
- 6mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation EvolutionGlobeNewswireNEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic
- 6mo agoALNYARCTDNLIOTLC+1When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in BiotechGlobeNewswireAUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector
- 7mo agoOTLCOncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline ProgressGlobeNewswireAGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical-stage biopharmaceutical company developing drugs for the treatment of
- 7mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance SpaceGlobeNewswireNEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brands
- 7mo agoDHREMROTLCROK+1AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesGlobeNewswireAUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond
- 7mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Operates at Intersection of Life Sciences, Advanced Digital Technologies,GlobeNewswireNEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brands
- 7mo agoAMZNHONNVDAOMCL+1AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory StandardsGlobeNewswireAUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality
- 7mo agoNGTFOTLCNightfood Holdings, Inc. (dba TechForce Robotics) Announces Strategic Joint Development Agreement with Oncotelic TherapeuticsGlobeNewswireTEMECULA, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- via IBN – Nightfood Holdings, Inc., (OTCQB:NGTF) doing business as TechForce Robotics, Inc., ("TechForce" or the "Company"), today announced the execution of a Joint
- 7mo agoOTLCSapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026GlobeNewswireAGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our"), a leader in RNA-based therapeutics, announced
- 7mo agoOTLCSapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual MeetingGlobeNewswireAGOURA HILLS, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our"), a leader in RNA-based therapeutics, announced
- 8mo agoOTLCNetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage PortfoliosGlobeNewswireAUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled "Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,"
- 8mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech EvolutionGlobeNewswireNEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic
- 8mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset TrendGlobeNewswireNEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic
- 8mo agoARWRJNJMGTXOTLC+1Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AGlobeNewswireAUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage
- 9mo agoOTLCOncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified PipelineGlobeNewswireAGOURA HILLS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN — Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology, immunotherapy,
- 10mo agoOTLCOncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge CorpusGlobeNewswireAGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our"), a leader in RNA-based therapeutics, announced
- 11mo agoOTLCOncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic CancerGlobeNewswireAGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) in collaboration with the Brush and Key Foundation, today announced the publication of a peer-reviewed research article
- 11mo agoOTLCOncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus NanomedicineGlobeNewswireAGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) 45% owned Joint Venture, Sapu Nano today announced new biomarker data identifying a molecular signature that predicts
- 11mo agoOTLCOncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral DosingGlobeNewswireAGOURA HILLS, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) 45% owned Joint Venture, Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results
- 11mo agoOTLCOncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide DrugsGlobeNewswireAGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that
- 11mo agoOTLCOncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV ValuationGlobeNewswireNEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB:OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic